Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — B&K Securities 'Trinity India' Conference 2023
36 slides from Iol Chemicals & Pharmaceuticals's conference presentation, Jun 3, 2023
Slide 1: Exchange filing cover letter for conference presentation
3rd June 2023 IOLCP/CGC/2023 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Presentation at B&K S
Slide 2: IOL Chemicals and Pharmaceuticals Limited - Trinity India Conference
IOL Chemicals and Pharmaceuticals Limited ‘TRINITY INDIA’ B&K Securities Conference June 2, 2023
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 4: Index
Index 01 Company Overview 02 Business Overview 03 ESG Initiatives IOL – Overview Pharmaceutical-Building API Portfolio Sustainability Initiatives Milestones • Current API Portfolio ESG Footprint – Environment Core Management Team • Current Intermediates Portfolio • Emission Reduction Report Board of
Slide 5: Company Overview
COMPANY OVERVIEW 4
Slide 6: IOL Chemicals & Pharma – Overview
IOL Chemicals & Pharma – Overview Incorporated in 1986, IOL is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2650+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free c
Slide 7: Milestones
Milestones ▪ 2009 - Commencement of ▪ 2015 - USFDA, EIR for ▪ 2019 - Unit-06 for ▪ 1996 - Commencement of IBB, MCA and Acetyl ▪ Commenced Ibuprofen Pantoprazole (Dedicated) Ethyl Acetate Plant Chloride Plants commercial production ▪ 2016 - Unit-03 for new ▪ 2020 - Unit-07 Metformin ▪ 1999 - Commence
Slide 8: Core management team
Core management team Varinder Gupta Vikas Gupta Abhiraj Gupta Kushal Kumar Rana Vikas Vij (Managing Director) (Joint Managing (Executive Director*) (Director – Works) (Chief Executive Director) Officer*) ▪ Wide and rich experience ▪ Academically equipped with • Possesses requisite ▪ Bachelor’s in Ch
Slide 9: Independent Directors
Independent Directors Rajender Mohan Malla Dr. Sandhya Mehta Harpal Singh Sharad Tyagi (Chairman and Independent Director) (Independent Director) (Independent Director) (Independent Director) ▪ Over 35 years of intrapreneurship ▪ With four decades of experience ▪ Dr. Sandhya is working as the ▪ Over
Slide 10: Certifications
Certifications State Food and Drug Administration Certificate of Occupational Approved USFDA facility since EUGMP Certification in 2013, ISO 9001:2015, 14001:2015 & Manufacturing License, GMP Certified Kosher Health & Safety Management 2015, recertified in 2019 2017 & Recertification in 2020 45001:2
Slide 11: Manufacturing facilities
Manufacturing facilities 1 API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology 2 Manufacturing facilities involves – Reactions, Filteration, Centrifugation, Drying, Blending & Sieving, Micronization operation Research
Slide 12: Business Overview
BUSINESS OVERVIEW 11
Slide 13: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOL is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT Product application across various therapeutic
Slide 14: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio 13
Slide 15: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio Product pipeline Current Intermediates Portfolio Therapeutic Under Under Product Name API Product Name Category development Validations L-Prolinamide Hydrochloride Vildagliptin Quetiapine Fumarate Anti-psychotic Completed Completed 3-Amino-1-adamantanol Vilda
Slide 16: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOL first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • India’s seco
Slide 17: ESG Initiatives
ESG INITIATIVES 16
Slide 18: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment Sustainability Initiatives • Committed to ensure that our operations have minimal impact on the environment • Constantly monitoring environmental footprints and ● FY 2021-22 taken as baseline year for Scope 1 and 2 Emission and impl
Slide 19: ESG Footprint - Environment
ESG Footprint - Environment Focused Environment Stewardship 95% Water neutral 48% Reduction in Greening Sustainable Practices Waste Management carbon intensity • Regular donation of plants and tree • Modern and well-equipped effluent • Storage of hazardous waste in guards to the Forest Department tr
Slide 20: ESG Footprint - Environment: Greenhouse Gas Emission Report
ESG Footprint - Environment Greenhouse Gas Emission Report Scope 1/Category 1 Scope 2/Category 2 Scope 3/Category 3 • Stationary Combustion • Purchased Electricity • Upstream transportation and distribution (Coal,HSD) • Capital Goods – Transportation • Refrigerants (R-22) • HW Transportation • Fire
Slide 21: ESG Footprint - Environment: Emission Reduction Initiatives
ESG Footprint - Environment Emission Reduction Initiatives under Scope 1/Category 1 – FY22-23 Date of Sr. No. Initiative Objective tCO2e Commissioning Energy saving by replacement of Old 12.1 MW Turbine with new Steam saving Activity by 1 18.01.23 designed efficient 12.4 MW Turbine with same input p
Slide 22: ESG Footprint - Social
ESG Footprint - Social Healthcare Education Social upliftment • Dialysis machines, Portable X-Rays • 15 schools in Barnala and 7 • Provided Water Coolers, Washing machine donated at Civil Hospital, schools in Ludhiana Machine, Refrigerator, LED’s & Barnala • Smart classroom facilities along Speaker,
Slide 23: ESG Footprint - Governance
ESG Footprint - Governance • Committed to serving the best interests of all stakeholders • Implemented a sound and well structured corporate governance system that enables us to operate more efficiently, mitigate business risks & protect the stakeholders’ interests • Directs the focus of our busines
Slide 24: Navigating the Path to Resurgence
NAVIGATING THE PATH TO RESURGENCE 23
Slide 25: Four key areas to drive next leg of growth
Four key areas to drive next leg of growth… Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Pharma & utilization Markets Business Chemicals Focus on efficiently utilizing Plan to enhance our product Target non- Ibuprofen business Capac
Slide 26: Improved asset utilization
Improved asset utilization • All our product operations are undertaken at our manufacturing facilities based in Barnala, Punjab • Each plant operated and API Plants Specialty maintained as per current GMP Chemical Plants (cGMP) standards • Plants approved by EUGMP with 3 Dedicated dedicated solvent
Slide 27: Outreach to regulated markets for sustained business
Outreach to regulated markets for sustained business EU GMP Certification from National Institute • Received the European Directorate for • Received the REACH certification for of Pharmacy and Nutrition, Hungary the Quality of Medicines & supply of ethyl acetate across the Ibuprofen HealthCare’s (ED
Slide 28: Expanding the non-Ibuprofen business – 1/2
Expanding the non-Ibuprofen business – 1/2 FY18 FY22 FY23 362, 37% 1181, 54% 955, 43% 35, 3% 476, 22% 351, 16% 586, 60% 652, 30% 786, 35% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's • Contribution of non-Ibuprofen drugs has increased from Rs.35 cro
Slide 29: Expanding the non-Ibuprofen business – 2/2
Expanding the non-Ibuprofen business – 2/2 (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an Regulatory Filings: CEP installed capacity of approved; US DMF filed 3,600 MT/Annum, with a backward integration process (Antiplatelet drug, used in cardiovascular (Ant
Slide 30: Leveraging strong domestic demand through expansion – 1/2
Leveraging strong domestic demand through expansion – 1/2 • IOL is focusing on other APIs like World Pharmaceutical Industry Paracetamol, Metformin, Pantoprazole, Clopidogrel and Lamotrigine to diversify from Ibuprofen business • Investment in expanding the Paracetamol capacity to 3,600 MT from 1,80
Slide 31: Leveraging strong domestic demand through expansion – 2/2
Leveraging strong domestic demand through expansion – 2/2 Indian Specialty Chemical Industry Year Chemical Specialty Chemicals Growth 2021 US$170-180 Billion US$32 Billion 9-10% 11.5% (2021-27) 2040 US$ 850-1000 Billion US$140-190 Billion 7-9.5% (2027-40) Source: McKinsey – India: The Next Chemicals
Slide 32: Financial Highlights
FINANCIAL HIGHLIGHTS 31
Slide 33: 5-years Performance
5-years Performance Operational Revenue (Rs Cr) EBITDA (Rs Cr) and EBITDA Margin (%) PAT (Rs Cr) and PAT Margin (%) 2,216 2,243 30.9% 30.9% 22.3% 1,911 1,991 18.9% 1,696 24.8% 13.0% 14.0% 990 12.7% 11.2% 7.5% 6.2% 2.8% 126 420 590 616 288 252 28 237 361 445 166 140 FY18 FY19 FY20 FY21 FY22 FY23 FY18
Slide 34: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment (Rs. crore) 300 13 15 400 368 90 11 350 80 80 10 297 303 303 300 285 250 70 5 250 60 200 -1 0 50 -3 150 40 200 -6 33 35 40 100 -5 50 24 30 276 279 238 218 219 150 -10 0 20 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q4FY22 Q1FY
Slide 35: Summary
Summary Pharmaceutical Segment • Most reliable partner for reputed pharmaceutical players globally, by providing them with high-quality input products, which are key ingredients used for making essential and advanced medicines. • Moving towards a well diversified product portfolio, that is a shift t
Slide 36: Thank You
Company : Investor Relations Advisors : IOL Chemicals & Adfactors PR Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, CFO Snighter Albuquerque snighter.a@adfactorspr.com THANK YOU pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — B&K Securities 'Trinity India' Conference 2023 on 6ix